CVS vs MRK: fair value comparison
CVS Health Corporation and Merck & Co., Inc. · Updated 2026-09-06
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CVS currently sits closer to the top of our discount ranking. MRK carries the stronger quality grade.
| CVS | MRK | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $96.74 | $150.33 |
| 12-month range | $72.49–$105.37 | $82.49–$149.86 |
| Sector rank | #92 of 113 Healthcare | #95 of 113 Healthcare |
| Quality grade | F | C |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: CVS fair value analysis · MRK fair value analysis